Physicians at Mount Sinai are exploring new avenues of clinical investigation, based on the beneficial response of patients to tPA in a small, preliminary case series. Use of tPA, short for tissue plasminogen activator, is common in emergencies such as ischemic stroke, pulmonary embolism, and other dangerous situations where its clot-busting clinical benefits outweigh the risks.
In these five critically ill COVID-19 patients, tPA was used as a life-saving measure, but its success is leading the team to new questions about the course of the disease and options for treating it. Further studies are needed to determine whether lung clots are the cause or the effect of disease progression.
This work and other evidence are informing rapidly-evolving guidelines on the incorporation of anticoagulation therapies for COVID-19 treatment. Learn more from Mt. Sinai.